Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment. / Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Linde, Louise; Jacobsson, Lennart; Nissen, Michael J.; Kristianslund, Eirik Klami; Santos, Maria José; Nordström, Dan; Rotar, Ziga; Gudbjornsson, Bjorn; Onen, Fatos; Codreanu, Catalin; Lindström, Ulf; Möller, Burkhard; Kvien, Tore K.; Barcelos, Anabela; Eklund, Kari K.; Tomšič, Matija; Love, Thorvardur Jon; Can, Gercek; Ionescu, Ruxandra; Loft, Anne Gitte; Mann, Herman; Pavelka, Karel; van de Sande, Marleen; van der Horst-Bruinsma, I. E.; Suarez, Manuel Pombo; Sánchez-Piedra, Carlos; Macfarlane, Gary J.; Iannone, Florenzo; Michelsen, Brigitte; Hyldstrup, Lise Hejl; Krogh, Niels Steen; Østergaard, Mikkel; Hetland, Merete Lund.
I: Joint Bone Spine, Bind 91, Nr. 4, 105729, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
AU - Ørnbjerg, Lykke Midtbøll
AU - Brahe, Cecilie Heegaard
AU - Linde, Louise
AU - Jacobsson, Lennart
AU - Nissen, Michael J.
AU - Kristianslund, Eirik Klami
AU - Santos, Maria José
AU - Nordström, Dan
AU - Rotar, Ziga
AU - Gudbjornsson, Bjorn
AU - Onen, Fatos
AU - Codreanu, Catalin
AU - Lindström, Ulf
AU - Möller, Burkhard
AU - Kvien, Tore K.
AU - Barcelos, Anabela
AU - Eklund, Kari K.
AU - Tomšič, Matija
AU - Love, Thorvardur Jon
AU - Can, Gercek
AU - Ionescu, Ruxandra
AU - Loft, Anne Gitte
AU - Mann, Herman
AU - Pavelka, Karel
AU - van de Sande, Marleen
AU - van der Horst-Bruinsma, I. E.
AU - Suarez, Manuel Pombo
AU - Sánchez-Piedra, Carlos
AU - Macfarlane, Gary J.
AU - Iannone, Florenzo
AU - Michelsen, Brigitte
AU - Hyldstrup, Lise Hejl
AU - Krogh, Niels Steen
AU - Østergaard, Mikkel
AU - Hetland, Merete Lund
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024
Y1 - 2024
N2 - Objective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. Methods: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). Results: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67–70%) and 66% (64–68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. Conclusion: Two-thirds of patients remained on TNFi at 12 months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6 months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.
AB - Objective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. Methods: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). Results: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67–70%) and 66% (64–68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. Conclusion: Two-thirds of patients remained on TNFi at 12 months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6 months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.
KW - Epidemiology
KW - Psoriatic arthritis
KW - TNF-inhibitors
KW - Treatment withdrawal
U2 - 10.1016/j.jbspin.2024.105729
DO - 10.1016/j.jbspin.2024.105729
M3 - Journal article
C2 - 38582359
AN - SCOPUS:85190446423
VL - 91
JO - Joint Bone Spine
JF - Joint Bone Spine
SN - 1297-319X
IS - 4
M1 - 105729
ER -
ID: 389549035